TRIM25 and cancer: Specifically, targeting the RING subfamily of E3 ubiquitin ligases including TRIM25, which can confer specificity to the ubiquitin machinery, has shown promise against cancer in preclinical and clinical trials and is a widely recognized approach [142,143].